Budesonide in the first line treatment of patients with autoimmune hepatitis

Budesonide is a glucocorticoid characterized by its local action, with a low systemic bioavailability. Since the original trial comparing budesonide with prednisone in 2010, it is recommended as an effective alternative for the treatment of non-severe acute or chronic autoimmune hepatitis. In this d...

Full description

Saved in:
Bibliographic Details
Published inGastroenterología y hepatología
Main Authors Olivas, Ignasi, Cobreros, Marina, Londoño, María-Carlota, Díaz-González, Álvaro
Format Journal Article
LanguageEnglish
Published Spain 01.08.2022
Subjects
Budesonide
Hepatitis autoinmune
Biochemical remission
Autoimmune hepatitis
Budesonida
Remisión bioquímica
Prednisone
Prednisona
Online AccessGet more information

Cover

More Information
Summary:Budesonide is a glucocorticoid characterized by its local action, with a low systemic bioavailability. Since the original trial comparing budesonide with prednisone in 2010, it is recommended as an effective alternative for the treatment of non-severe acute or chronic autoimmune hepatitis. In this document, we review the general pharmacologic properties of glucocorticoids, the available evidence for the use of budesonide as first line option for autoimmune hepatitis as well as the safety profile of the drug.
ISSN:0210-5705
DOI:10.1016/j.gastrohep.2021.11.012